Chemistry:MW073

From HandWiki

MW073 is a serotonin 5-HT2B receptor antagonist which is used in scientific research.[1][2][3][4][5] It is a highly selective antagonist of the serotonin 5-HT2B receptor.[3][2] The drug is orally active in animals and is said to have a favorable drug-like profile.[3][2] It produces antiaggressive effects without causing sedation or altering locomotor activity or anxiety in an animal model of Alzheimer's disease.[3][2] Similarly, it produces neuroprotective, neurorestorative, and pro-cognitive-like effects in such models.[3][2][5] MW073 was first described in the scientific literature by 2024.[4][2][3][5] There is interest in MW073 for the potential treatment of Alzheimer's disease and other conditions.[3][2]

See also

  • List of investigational aggression drugs
  • Minaprine

References

  1. "Delving into the Latest Updates on MW073 with Synapse". 9 May 2026. https://synapse.patsnap.com/drug/c1ab516e2a3c4dd9b62ac2c719a099ed. 
  2. 2.0 2.1 2.2 2.3 2.4 2.5 2.6 "Optimized 5-HT2b inhibitors for neuropsychiatric syndromes with cognitive dysfunction". Alzheimer's & Dementia (New York, N. Y.) 11 (1). 2025. doi:10.1002/trc2.70073. PMID 40151398. 
  3. 3.0 3.1 3.2 3.3 3.4 3.5 3.6 "The Highly Selective 5-HT2B Receptor Antagonist MW073 Mitigates Aggressive Behavior in an Alzheimer's Disease Mouse Model". Cells 15 (3). February 2026. doi:10.3390/cells15030273. PMID 41677635. 
  4. 4.0 4.1 "The 5HT2b Receptor in Alzheimer's Disease: Increased Levels in Patient Brains and Antagonist Attenuation of Amyloid and Tau Induced Dysfunction". Journal of Alzheimer's Disease 98 (4): 1349–1360. 2024. doi:10.3233/JAD-240063. PMID 38578894. 
  5. 5.0 5.1 5.2 "MW073 Treatment Attenuates Synaptic Dysfunction, Cognition-Related Behavior Deficits, and Aggression in Alzheimer's Disease Models (Abstract ID: 273213)". The Journal of Pharmacology and Experimental Therapeutics 393 (5). 2026. doi:10.1016/j.jpet.2026.104835.